Return to homepagePandemic Pact

Vaccine and Treatment Evaluation Units (VTEU)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UM1AI148575-02S4

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $2,614,800

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    PROFESSOR HANA EL SAHLY

  • Research Location

    United States of America

  • Lead Research Institution

    BAYLOR COLLEGE OF MEDICINE

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 3 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase III

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

ABSTRACT This supplement request is for a Phase 3, randomized, observer-blind, placebo-controlled study to evaluate the efficacy, safety and immunogenicity, of a SARS-CoV-2 recombinant spoke protein nanoparticle vaccine (SARS-CoV-2 rS) with Matric-M1TM adjuvant in adult participants over 18 years of age who have no known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 and/or SARS-CoV-2 infection. This request also relates to other COVID 19 activities.